Properties (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
tablet
suspension |
| gptkbp:brand |
gptkb:Azulfidine
|
| gptkbp:chemicalFormula |
sulfonamide
C11H12N4O2S |
| gptkbp:clinicalTrials |
studies on Crohn's disease
studies on rheumatoid arthritis studies on ulcerative colitis |
| gptkbp:composedOf |
by coupling with pyridine
by diazotization reaction from sulfanilamide |
| gptkbp:contraindication |
severe liver disease
severe kidney disease hypersensitivity to sulfonamides |
| gptkbp:dissolved |
soluble in water
soluble in alcohol insoluble in ether |
| gptkbp:endOfLife |
6 to 12 hours
|
| gptkbp:hasFacilities |
252.30 g/mol
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sulfapyridine
|
| gptkbp:interactsWith |
diuretics
warfarin methotrexate |
| gptkbp:isATypeOf |
144-83-2
|
| gptkbp:issuedBy |
oral medication
|
| gptkbp:lastProduced |
1950s
|
| gptkbp:locatedIn |
1930s
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:relatedTo |
sulfadiazine
sulfamethoxazole sulfanilamide |
| gptkbp:research |
development of combination therapies
investigations into resistance mechanisms ongoing studies for new indications |
| gptkbp:research_areas |
anti-inflammatory drug
|
| gptkbp:route |
oral
|
| gptkbp:safety |
generally well tolerated
monitoring required for long-term use |
| gptkbp:sideEffect |
headache
nausea rash |
| gptkbp:triggerType |
inhibits bacterial folic acid synthesis
|
| gptkbp:usedFor |
treatment of rheumatoid arthritis
treatment of ulcerative colitis |
| gptkbp:waterManagement |
urine
|